Premium
Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator
Author(s) -
Slotman Berend J.,
Nauta Jos J. P.,
Rao B. Ramanath
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900815)66:4<740::aid-cncr2820660423>3.0.co;2-h
Subject(s) - medicine , serous fluid , ovarian cancer , progesterone receptor , proportional hazards model , androgen receptor , stage (stratigraphy) , estrogen receptor , ovary , estrogen , gastroenterology , oncology , cancer , gynecology , urology , breast cancer , prostate cancer , biology , paleontology
Estrogen (ER), progesterone (PR), and androgen receptors (AR) were determined by saturation analysis in 100 cases of primary ovarian cancer and correlated with patient survival. The mean follow‐up period was 5.4 years (range, 4 to 6.5 years). Positivity for PR was associated with a significantly better survival rate ( P < 0.05). A similar observation was made for AR ( P < 0.05). Tumor ER content did not correlate with survival. Ten patients with tumors that had negative results for both PR and AR all died of the disease. In 91 cases of serous, endometrioid, and mucinous carcinomas, grade, stage, and tumor PR content, but not AR content, were identified as independent prognostic factors with the use of the Cox proportional hazards model. The relative risk of patients with PR‐negative tumors was 2.3 times higher than that of patients with tumors containing high (≥ 30 fmol/ mg) PR levels.